

Cost-effectiveness of internet-delivered

2 cognitive behaviour therapy for body dysmorphic disorder: results from a 4 randomised controlled trial

Oskar Flygare¹, Erik Andersson², Gjermund Glimsdal², David Mataix-Cols¹,

6 Diana Djurfeldt¹, Christian Rück¹, Jesper Enander¹

Author information

8 Corresponding author: Oskar Flygare, oskar.flygare@ki.se. M46, Karolinska
University Hospital, SE-141 86 Huddinge, Sweden.

10 Affiliations:

- 1 Centre for Psychiatry Research, Department of Clinical Neuroscience,
12 Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm,
Sweden
- 14 - 2 Division of Psychology, Department of Clinical Neuroscience, Karolinska
Institutet, Sweden

16 E-mail addresses:

- Oskar Flygare (oskar.flygare@ki.se)
- 18 • Erik Andersson (erik.m.andersson@ki.se)
- Gjermund Glimsdal (g.glimsdal@gmail.com)
- 20 • David Mataix-Cols (david.mataix.cols@ki.se)
- Diana Djurfeldt (diana.djurfeldt@ki.se)
- 22 • Christian Rück (christian.ruck@ki.se)
- Jesper Enander (jesper.enander@ki.se)

24 Abstract

Objectives: To evaluate the cost-effectiveness of internet-delivered cognitive
26 behaviour therapy for body dysmorphic disorder (BDD-NET).

Design: Secondary cost-effectiveness analysis from a randomised controlled trial
28 on BDD-NET versus online supportive psychotherapy.

Setting: Academic medical centre.

30 **Participants:** Self-referred adult patients with a primary diagnosis of body
dysmorphic disorder and a score of 20 or higher on the modified Yale-Brown
32 obsessive compulsive scale (n = 94). Patients receiving concurrent psychotropic
drug treatment were included if the dose had been stable for at least two months
34 and remained unchanged during the trial.

Interventions: Participants received either BDD-NET (n = 47) or online
36 supportive psychotherapy (n = 47) for 12 weeks.

Primary and secondary outcome measures: The primary outcome measures
38 were cost-effectiveness and cost-utility from a societal perspective, using
remission status from a diagnostic interview and quality-adjusted life years from
40 EQ-5D, respectively. Secondary outcome measures were cost-effectiveness and
cost-utility from a health care perspective and the clinic's perspective.

42 **Results:** Compared to supportive psychotherapy, BDD-NET produced one
additional remission for an average societal cost of \$4132. The cost-utility
44 analysis showed that BDD-NET generated one additional QALY to an average
cost of \$14319 from a societal perspective.

46 **Conclusions:** BDD-NET is a cost-effective treatment for body dysmorphic
disorder, compared to online supportive psychotherapy. The efficacy and cost-
48 effectiveness of BDD-NET should be directly compared to face-to-face cognitive
behaviour therapy.

50 **Trial registration:** NCT02010619

Strengths and limitations of this study

- 52 • This is the first cost-effectiveness evaluation of a novel internet-delivered
treatment designed to increase access to cognitive behaviour therapy for
54 patients with body dysmorphic disorder
- Cost estimations were self-rated and might not capture all costs associated
56 with treatment
- The self-referred participants were likely motivated to undergo treatment.

58 **Keywords:** “body dysmorphic disorder, cognitive behaviour therapy, cost-
effectiveness”

60 Word count: 2961

Background

62 Body dysmorphic disorder (BDD) is characterised by an intense pre-occupation
with perceived flaws in appearance that are not noticeable or appear slight to
64 others. Cognitive behaviour therapy (CBT) is an effective treatment for BDD (1–
4), but few patients receive this evidence-based treatment for BDD. In one online
66 survey, only 18% of patients with BDD had ever received CBT (5). Barriers to

treatment include shame and stigma associated with BDD, the costs of treatment, and belief that a treatment would not work (5,6). In addition, there is a shortage of specialised CBT therapists, particularly in areas far away from universities and CBT training centres (7). Thus, specialist CBT for BDD is inaccessible for most patients.

Internet-delivered cognitive behaviour therapy (ICBT) has been developed for a range of mental health disorders in an effort to improve access to evidence-based treatment (8). ICBT interventions include the same content as regular CBT and differ only in the mode of delivery: the patient logs into a secure web-based platform to access treatment content and communicate with a therapist. Previous studies have shown that therapist-guided ICBT for BDD (BDD-NET) is an efficacious treatment for adults with BDD, with effects sustained up to two years after treatment (9–11). An advantage of remote treatments such as BDD-NET is that they require less therapist time per patient, enabling more patients to access therapy and reducing costs. However, the cost-effectiveness of BDD-NET has not been formally evaluated. Here, we analysed cost data from our controlled trial (9) and evaluated the cost-effectiveness of BDD-NET compared to online supportive psychotherapy. We hypothesised that BDD-NET would be cost-effective from societal, health care, and the clinic’s perspectives.

Methods

Trial design

This study reports planned secondary cost-effectiveness analyses from a randomised controlled trial comparing BDD-NET to supportive psychotherapy (N

90 = 94) (9). The study was approved by the regional ethical review board in
Stockholm (2013/1773-31/4) and pre-registered at clinicaltrials.gov
92 (NCT02010619). Recruitment, treatment, and follow-up in the original study was
conducted between November 2013 and January 2015. The results are reported in
94 accordance with the CHEERS reporting guidelines for health economic
evaluations (12).

96 **Participants**

Included participants had a primary diagnosis of BDD according to the Diagnostic
98 and Statistical Manual of Mental Disorders, 5th edition (DSM-5; (13)), were at
least 18 years old, had access to the internet, and a score of 20 or above on the
100 modified Yale-Brown obsessive-compulsive scale for BDD (BDD-YBOCS; (14)).
Participants who were taking psychotropic drugs were asked to keep their dose
102 stable during the study period. Exclusion criteria were initiation or changes in
psychotropic drug treatment within two months before enrolment, completed CBT
104 for body dysmorphic disorder within the past 12 months, ongoing psychological
treatment, current substance dependence, bipolar disorder or psychosis, acute
106 suicidal ideation, or a severe personality disorder that could jeopardize
participation in treatment (such as borderline personality disorder with self harm).

108 **Interventions**

BDD-NET

110 BDD-NET was delivered through a secure online platform hosted at a dedicated
hospital server with encrypted traffic. The treatment was based on a validated
112 CBT protocol for body dysmorphic disorder (15), contained eight text-based

modules accompanied by worksheets and homework assignments, and lasted 12
 114 weeks. Participants were asynchronously supported by a therapist through a built-
 in email system on the BDD-NET webpage and could log in to send emails at any
 116 time. Therapists would then review and respond to messages within 36 hours on
 weekdays.

118 The therapists involved were four clinical psychology students with basic clinical
 training but with no prior experience of treating BDD. They received weekly
 120 supervision sessions with an experienced clinician (author JE) who also monitored
 messages on the platform to ensure treatment integrity and adherence to protocol.

122 *Online supportive psychotherapy*

Participants receiving online supportive psychotherapy had access to the email
 124 system on the BDD-NET webpage and received support in a similar way to BDD-
 NET. The therapists used counselling techniques such as reflecting, empathising
 126 and summarising in order to provide the same level of caregiver attention as
 BDD-NET. Notably, the supportive therapy did not include core parts of BDD-
 128 NET such as exposure with response prevention. For more detailed descriptions of
 the interventions, please see the main outcome paper (9).

130 **Measures**

Clinical outcomes

132 The cost-effectiveness analyses were based on remission status and quality-
 adjusted life years (QALYs). Remission was defined as no longer meeting
 134 diagnostic criteria for body dysmorphic disorder in a structured interview with a
 clinician, blinded to treatment allocation. QALYs were estimated based on the

136 self-rated EuroQol (EQ-5D) which is divided into five health domains: mobility,
self-care, pain/discomfort, daily activities, and anxiety/depression. An index
138 QALY score is then calculated ranging from 0 (dead) to 1 (perfect health) (16).

Health economic measures

140 We used the Trimbos questionnaire for costs associated with psychiatric illness
(TIC-P) to gather information on self-rated costs in the past month (17). Costs
142 were analysed from a societal perspective by including all direct and indirect,
medical and non-medical costs (e.g., productivity losses, sick leave). From a
144 health care perspective, costs directly associated with treatment and costs from
other health care visits and medications were included. Finally, costs from the
146 clinic's perspective included only the cost of providing treatment (e.g., therapist
salary). Costs for medications were calculated from market prices, and health care
148 visit costs were based on tariffs from official listings for the Swedish health care
system (see supplemental materials). Productivity losses were based on the mean
150 gross earning in Sweden in 2014 (188 SEK), and domestic work cutback was
estimated using the hourly tariff of €14 (18). The TIC-P was administered at pre-
152 treatment, post-treatment and follow-up. Costs were summarised in Swedish
Crowns, extrapolated to 12 weeks in order to cover the full duration between
154 assessments, and converted to US dollars based on purchasing power parities for
the year 2014 where 6.861 SEK paid one USD.

156 Statistical analyses

All analyses were intention-to-treat with the assumption that data were missing at
158 random. Costs from the three perspectives (societal, health care, clinic) were
analysed with remission status and QALY change from pre-treatment to post-

160 treatment and follow-up as outcomes, respectively. Mixed-effects linear
regression for repeated measures were used for outcomes and costs, with fixed
162 effects of group and time, their interaction, as well as a random intercept term.
Missing values were estimated using maximum likelihood estimation in the
164 mixed-effects models, and non-parametric bootstrapping (1000 replications) was
used to estimate group differences which were based on the group * time
166 interaction effects. The “net benefit” approach was used by estimating the
probability of cost-effectiveness under different societal willingness-to-pay
168 scenarios (19). Standardised Cohen’s *d* effect sizes were estimated for both
within-group and between-group changes based on the least-squares means from
170 the models, using the residual standard deviation of random effects as sigma (20).
We used R version 4.0.2 (21) for all analyses and the analytical code is available
172 on the Open Science Framework <https://doi.org/10.17605/OSF.IO/DC69E>.

Results

174 Completion rates and participant characteristics

A majority of the participants were female ($n = 80$ (85%)) and the average age of
176 all the participants was 32.6 (SD = 11.97). See table 1 for demographic and
baseline assessment information for both treatment groups. All 94 participants
178 completed the post-treatment diagnostic interview, and at follow-up, 85 (90%)
participants completed the diagnostic interview (BDD-NET: 40/47 = 85%,
180 supportive therapy: 45/47 = 96%). Completion rates for EQ-5D were similar, with
92 (98%) assessments (BDD-NET: 45/47 = 96%, supportive therapy: 47/47 =
182 100%) at post treatment, and 80 (85%) assessments completed at follow-up

(BDD-NET: 36/47 = 77%, supportive therapy: 44/47 = 94%). Completion rates
 184 for the TIC-P cost assessment were high with 91 (97%) responses at post
 treatment (BDD-NET: 45/47 = 96%, supportive therapy: 46/47 = 98%) and 79
 186 (84%) responses at follow-up (BDD-NET: 36/47 = 77%, supportive therapy:
 43/47 = 91%). Figure 1 shows participant flow through the different assessment
 188 points.

INSERT FIGURE 1 HERE

190 **Caption:** *Figure 1. Diagram of participant flow and completion of measures.*
Abbreviations: BDD-NET, internet-delivered therapist-guided cognitive
 192 *behaviour therapy for body dysmorphic disorder; EQ-5D, EuroQol 5-*
Dimensions; TIC-P, Trimbos questionnaire for costs associated with psychiatric
 194 *illness.*

Table 1. Sample characteristics		
	Online supportive therapy	BDD-NET
n	47	47
Female, n (%)	41 (87%)	39 (83%)
Age (mean (SD))	31.32 (10.12)	33.87 (13.55)
Education, n (%)		
Primary school	6 (13%)	4 (9%)
High school	23 (49%)	31 (66%)
College/university	17 (36%)	11 (23%)
Doctorate	1 (2%)	1 (2%)
SSRI, n (%)	8 (17%)	5 (11%)
Pre-treatment BDD-YBOCS (mean (SD))	28.51 (4.55)	29.13 (5.02)
Pre-treatment EQ-5D (mean (SD))	0.75 (0.18)	0.71 (0.22)

Clinical efficacy

196 The proportion of remitters at post-treatment, i.e. participants that no longer met
diagnostic criteria according to the structured interview, were 32% [95% CI 20 to
198 46] in the BDD-NET group and 2% [95% CI 0 to 14] in the group that received
supportive therapy. Patients in the BDD-NET group were more likely to be in
200 remission at post-treatment (OR = 3.07, SE = 1.06, $p = .004$). At follow-up,

results were similar with a higher proportion of remitters in the BDD-NET group
 202 40% [95% CI 26 to 56] compared to supportive therapy 9% [95% CI 3 to 21] and
 corresponding difference in a direct comparison (OR = 1.92, SE = 0.62, $p = .002$).

204 EQ-5D QALY estimates at post-treatment were on average 0.73 [95% CI 0.66 to
 0.8] in the BDD-NET group and 0.67 [95% CI 0.61 to 0.74] in the supportive
 206 therapy group, with a small increase from pre-treatment in the BDD-NET group
 ($d = 0.08$ [95% CI -0.34 to 0.5]) and a medium-sized decrease in the supportive
 208 therapy group ($d = -0.39$ [95% CI -0.8 to 0.03]). At follow-up, the estimates were
 largely unchanged with an average of 0.8 [95% CI 0.72 to 0.87] in the BDD-NET
 210 group and 0.67 [95% CI 0.6 to 0.74] in the group that received supportive therapy.
 Within-group effect sizes from pre-treatment to follow-up were $d = 0.46$ [95% CI
 212 0 to 0.91] for BDD-NET and $d = -0.41$ [95% CI -0.83 to 0.01] for supportive
 therapy. The between-group effect sizes were small at post-treatment ($d = 0.29$
 214 [95% CI -0.22 to 0.8]) and medium at follow-up ($d = 0.69$ [95% CI 0.15 to 1.24]).

Costs

216 Costs from the societal perspective (e.g., including all direct, indirect, medical and
 non-medical costs) increased in the BDD-NET group ($b = \$928$) and decreased in
 218 the supportive therapy group ($b = \$-302$) groups over the course of treatment, and
 decreased in both groups between post-treatment and follow-up (BDD-NET: $b =$
 220 $\$-386$, supportive therapy: $b = \$-243$). Similarly, when looking at costs from a
 health care perspective (e.g., direct medical costs from visits and medications),
 222 costs from pre- to post-treatment increased in BDD-NET ($b = \$982$) and were
 stable in supportive therapy ($b = \$-55$). From post-treatment to follow-up, costs
 224 were stable (BDD-NET: $b = \$103$) or decreased slightly (supportive therapy: $b =$

\$-269). Detailed descriptions of costs for all sub-categories are shown in the
226 supplemental materials.

The cost of providing treatment from the clinic's perspective included the salary
228 cost of therapists and was estimated to \$946 for BDD-NET and \$461 for
supportive therapy. This cost corresponds to an average time of 15.7 minutes per
230 patient and week for BDD-NET and 7.7 minutes for supportive therapy.

Cost-effectiveness and cost-utility


232 The societal perspective

The cost-effectiveness of BDD-NET versus the supportive therapy control
234 treatment was investigated up until the 3-month controlled follow-up, after which
the control group was offered BDD-NET. The cost-effectiveness ICER at post-
236 treatment was $1231 / 0.3 = \$4132$ per case in remission. At follow-up, the
corresponding numbers were $1088 / 0.29 = \$3731$ per case in remission. BDD-
238 NET was cost-effective from a societal perspective, given that society is willing to
pay up to \$4132 per case in remission after treatment. A majority of ICERs from
240 bootstrapped samples were located in the northeast quadrant, confirming higher
efficacy and costs of BDD-NET compared to online supportive therapy (Figure
242 2A).

Cost-utility analyses (analyses of QALYs in relation to costs) indicated that the
244 societal cost for one additional QALY gain from BDD-NET versus supportive
therapy was $1231 / 0.09 = \$14319$ at post-treatment, and $1088 / 0.16 = \$6784$ at
246 follow-up. Given the small differences in EQ-5D QALY gain, BDD-NET
achieved 75% cost-utility at a societal willingness to pay of \$29000 at post-

248 treatment (Figure 2C). Again, the majority of ICERs from bootstrapped samples
were located in the northeast quadrant of the cost-effectiveness plane (Figure 2B).

250 **INSERT HIGH-RESOLUTION FIGURE HERE**



252 **Caption:** Figure 2. Pre-treatment to post-treatment cost-effectiveness of BDD-
NET compared to supportive therapy. Cost-effectiveness planes for BDD
254 remission rates (2A), QALYs (2B), and acceptability curves (2C). Costs are from
a societal perspective and based on the TIC-P questionnaire using Swedish health
256 care tariff listings and national statistics. Abbreviations: BDD-NET, internet-
delivered cognitive behaviour therapy for body dysmorphic disorder; ICER,
258 incremental cost-effectiveness ratio; QALYs, Quality-adjusted life years.

The health care perspective

260 From the health care perspective, which includes costs of health care and
medications (but excludes non-medical or indirect costs), the cost-effectiveness of
262 BDD-NET at post treatment was $1037 / 0.3 = \$3482$ per case in remission. The
cost-effectiveness of BDD-NET versus supportive therapy at follow-up was 1409
264 $/ 0.29 = \$4831$. Compared to supportive therapy, BDD-NET was estimated to
have an additional cost of \$3482 per case in remission, and the ICERs from

266 bootstrapped samples were located in the northeast quadrant of the cost-
effectiveness plane (see supplemental materials).

268 *The clinic's perspective*

The clinic's perspective includes the cost of delivering the interventions (in this
270 case, the cost of the psychologists' time). The cost-effectiveness of BDD-NET
compared to supportive therapy at post-treatment was $485 / 0.3 = \$1628$ per case
272 in remission. At follow-up, cost-effectiveness was $485 / 0.29 = \$1662$. Again, the
ICERs from bootstrapped samples were located in the northeast quadrant of the
274 cost-effectiveness plane.

Discussion

276 To our knowledge, this is the first cost-effectiveness study of a psychological
treatment for BDD. We found that therapist-guided internet-delivered cognitive
278 behaviour therapy for body dysmorphic disorder (BDD-NET) produced one
additional remission for an average societal cost of \$4132 and the cost-utility
280 analysis showed that BDD-NET generated one additional QALY to an average
price of \$14319 from a societal perspective, compared to online supportive
282 therapy. Results were similar when costs from a health care perspective and the
clinic's perspective were considered.

284 Previous studies on the cost-effectiveness internet-delivered cognitive behaviour
therapy (ICBT) for related disorders have found similar results. For example, (22)
286 found that an internet-delivered CBT for obsessive-compulsive disorder produced
an additional remission for \$672 and one additional QALY for \$4800 compared to
288 online supportive therapy. In cost-effectiveness analyses of ICBT for health

anxiety, savings of £1244 per additional case of remission were found compared
 290 to an attention control condition (23), and several forms of low-intensity
 treatments were found to be cost-effective compared to waiting list (£-134 to £416
 292 per additional case in remission) (24). Similarly, ICBT for depression was
 associated with a cost of €1817 for each additional reliably improved participant
 294 (25) and has been estimated to be cost-effective at a societal willingness to pay of
 £20 000 per additional QALY compared to usual care (26). Caution should be
 296 taken in directly comparing results from different studies since they may differ in
 the estimation of costs, outcome definitions, health care context, or comparators.
 298 Keeping this limitation in mind, a meta-analysis of ICBT for various conditions
 found that the treatments are cost-effective options by providing large clinical
 300 gains at relatively low cost (27).

The results should be viewed in light of several limitations. First, the current study
 302 used self-reported costs from the TIC-P, which might not capture all costs
 associated with treatment. However, the cost estimations from the TIC-P are
 304 reliable and correspond well to costs estimated from medical registrations (28).
 Second, BDD-NET was compared to supportive psychotherapy which is not an
 306 established treatment for BDD, however face to face supportive psychotherapy
 was associated with comparable gains to CBT for BDD in a recent randomised
 308 controlled trial, indicating that it is an effective treatment for some patients with
 BDD (3). Third, participants in this study were self-referred and thus likely to be
 310 motivated to undergo treatment. This may not be representative for the whole
 population of patients with BDD, who may have poor insight and be less
 312 motivated to seek help for their problems.

Future research should directly compare the efficacy and cost-effectiveness of
 314 BDD-NET to face-to-face CBT for BDD, which together with SSRI medication,
 is a first line treatment for BDD. Additionally, evaluation of BDD-NET in regular
 316 psychiatric care is needed as these patients may differ in level of insight,
 psychiatric comorbidity and willingness to undergo psychological treatment for
 318 their BDD, compared to self-referred participants.

In conclusion, BDD-NET is a cost-effective treatment for BDD, compared to
 320 online supportive psychotherapy. The results have direct implications for rational
 decision-making in health care, where information on the cost-effectiveness of
 322 treatment alternatives can improve the distribution of limited resources, thus
 providing effective treatment to more patients at a minimal cost.

324

Article information

326 **Funding**

This research received no specific grant from any funding agency in the public,
 328 commercial or not-for-profit sectors. The original clinical trial was funded
 through the regional agreement on medical training and clinical research (ALF)
 330 between the Region Stockholm and Karolinska Institutet, the Swedish Research
 Council (no. K2013-61X-22168-01-3) and the Swedish Society of Medicine
 332 (Söderströmska K nigska sjukhemmet, no. SLS3B4451).

The funders had no part in the study design, in the collection, analysis and
 334 interpretation of data, in the writing of the report or in the decision to submit the
 article for publication.

336 **Ethical approval**

The regional ethical review board in Stockholm approved the protocol
 338 (registration ID: 2013/1773-31/4). All participants gave written informed consent.

Competing interests

340 None declared.

Contributors

342 JE and CR had the original idea for the study and, with DM-C, designed the trial
 variables and obtained funding. JE and CR were responsible for study
 344 supervision. OF carried out the statistical analysis and drafted the manuscript,

which was revised by EA, GG, DM-C, DD, CR and JE. All authors approved the
346 final version to be submitted.

Data sharing statement

348 The datasets analysed are not publicly available since they contain sensitive
personal identifying information and data sharing was not part of the written
350 informed consent, but are available from the corresponding author on reasonable
request. Statistical code is publicly available from the Open Science Framework
352 repository: <https://doi.org/10.17605/OSF.IO/DC69E>

References

- 354 1. Veale D, Anson M, Miles S, Pieta M, Costa A, Ellison N. Efficacy of Cognitive
Behaviour Therapy versus Anxiety Management for Body Dysmorphic Disorder:
356 A Randomised Controlled Trial. *Psychotherapy and Psychosomatics*. 2014
Jan;83(6):341–53.
- 358 2. Wilhelm S, Phillips KA, Didie E, Buhlmann U, Greenberg JL, Fama JM, et al.
Modular Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A
360 Randomized Controlled Trial. *Behavior Therapy*. 2014 Jan;45(3):314–27.
3. Wilhelm S, Phillips KA, Greenberg JL, O’Keefe SM, Hoepfner SS, Keshaviah
362 A, et al. Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive
Behavioral Therapy vs Supportive Psychotherapy for Adults With Body
364 Dysmorphic Disorder: A Randomized Clinical Trial. *JAMA psychiatry*. 2019
Apr;76(4):363–73.

- 366 4. Harrison A, Fernández de la Cruz L, Enander J, Radua J, Mataix-Cols D.
Cognitive-behavioral therapy for body dysmorphic disorder: A systematic review
368 and meta-analysis of randomized controlled trials. Clinical Psychology Review.
2016 Aug;48:43–51.
- 370 5. Marques L, Weingarden HM, Leblanc NJ, Wilhelm S. Treatment utilization
and barriers to treatment engagement among people with body dysmorphic
372 symptoms. Journal of Psychosomatic Research. 2011 Mar;70(3):286–93.
6. Buhlmann U. Treatment barriers for individuals with body dysmorphic
374 disorder: An internet survey. The Journal of Nervous and Mental Disease. 2011
Apr;199(4):268–71.
- 376 7. Shapiro DA, Cavanagh K, Lomas H. GEOGRAPHIC INEQUITY IN THE
AVAILABILITY OF COGNITIVE BEHAVIOURAL THERAPY IN ENG
378 LAND AND WALES. Behavioural and Cognitive Psychotherapy. 2003
Apr;31(2):185–92.
- 380 8. Andersson G, Titov N, Dear BF, Rozental A, Carlbring P. Internet-delivered
psychological treatments: From innovation to implementation. World Psychiatry.
382 2019 Feb;18(1):20–8.
9. Enander J, Andersson E, Mataix-Cols D, Lichtenstein L, Alström K, Andersson
384 G, et al. Therapist guided internet based cognitive behavioural therapy for body
dysmorphic disorder: Single blind randomised controlled trial. BMJ. 2016
386 Feb;352:i241.

10. Enander J, Ljótsson B, Anderhell L, Runeborg M, Flygare O, Cottman O, et
388 al. Long-term outcome of therapist-guided internet-based cognitive behavioural
therapy for body dysmorphic disorder (BDD-NET): A naturalistic 2-year follow-
390 up after a randomised controlled trial. *BMJ Open*. 2019 Jan;9(1):e024307.
11. Gentile AJ, La Lima C, Flygare O, Enander J, Wilhelm S, Mataix-Cols D, et
392 al. Internet-based, therapist-guided, cognitiveBehavioural therapy for body
dysmorphic disorder with global eligibility for inclusion: An uncontrolled pilot
394 study. *BMJ Open*. 2019 Mar;9(3):e024693.
12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et
396 al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
statement. *BMJ*. 2013 Mar;346:f1049.
- 398 13. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders (DSM-5). American Psychiatric Pub; 2013.
- 400 14. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C,
Goodman WK. A severity rating scale for body dysmorphic disorder:
402 Development, reliability, and validity of a modified version of the Yale-Brown
Obsessive Compulsive Scale. *Psychopharmacology Bulletin*. 1997;33(1):17–22.
- 404 15. Enander J, Ivanov VZ, Andersson E, Mataix-Cols D, Ljótsson B, Rück C.
Therapist-guided, Internet-based cognitiveBehavioural therapy for body
406 dysmorphic disorder (BDD-NET): A feasibility study. *BMJ Open*. 2014
Sep;4(9):e005923.

- 408 16. Rabin R, Charro F de. EQ-SD: A measure of health status from the EuroQol
Group. *Ann Med*. 2001;33(5):337–43.
- 410 17. Hakkaart-van Roijen L, Van Straten A, Donker M, Tiemens B, van Straten A,
Roijen L, et al. Trimbos/iMTA questionnaire for costs associated with psychiatric
412 illness (TiC-P). 2002 Jan;
18. Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van
414 Roijen L. Update of the Dutch manual for costing studies in health care. Prinja S,
editor. *PLOS ONE*. 2017 Nov;12(11):e0187477.
- 416 19. Drummond MF, Stoddart GL, Torrance GW, Sculpher MJ, O'Brian BJ.
Methods for the Economic Evaluation of Health Care Programmes. Third edition.
418 New York: Oxford University Press; 2005.
20. Russell VL. Emmeans: Estimated Marginal Means, aka Least-Squares Means.
420 2020.
21. R Core Team. R: A language and environment for statistical computing.
422 Vienna, Austria: R Foundation for Statistical Computing; 2020.
22. Andersson E, Hedman E, Ljótsson B, Wikström M, Elveling E, Lindefors N,
424 et al. Cost-effectiveness of internet-based cognitive behavior therapy for
obsessive-compulsive disorder: Results from a randomized controlled trial.
426 *Journal of Obsessive-Compulsive and Related Disorders*. 2015 Jan;4:47–53.
23. Hedman E, Andersson E, Lindefors N, Andersson G, Rück C, Ljótsson B.
428 Cost-effectiveness and long-term effectiveness of internet-based cognitive

- behaviour therapy for severe health anxiety. *Psychological Medicine*. 2013
 430 Feb;43(2):363–74.
24. Axelsson E, Andersson E, Ljótsson B, Hedman-Lagerlöf E. Cost-effectiveness
 432 and long-term follow-up of three forms of minimal-contact cognitive behaviour
 therapy for severe health anxiety: Results from a randomised controlled trial.
 434 *Behaviour Research and Therapy*. 2018 Aug;107:95–105.
25. Warmerdam L, Smit F, van Straten A, Riper H, Cuijpers P. Cost-utility and
 436 cost-effectiveness of internet-based treatment for adults with depressive
 symptoms: Randomized trial. *Journal of Medical Internet Research*. 2010
 438 Dec;12(5):e53.
26. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D. Cost-
 440 effectiveness of therapist-delivered online cognitive-behavioural therapy for
 depression: Randomised controlled trial. *The British Journal of Psychiatry: The*
 442 *Journal of Mental Science*. 2010 Oct;197(4):297–304.
27. Donker T, Blankers M, Hedman E, Ljótsson B, Petrie K, Christensen H.
 444 Economic evaluations of Internet interventions for mental health: A systematic
 review. *Psychological Medicine*. 2015 Dec;45(16):3357–76.
28. Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-
 446 Cornelis C, Tan Swan S, et al. Feasibility, reliability and validity of a
 448 questionnaire on healthcare consumption and productivity loss in patients with a
 psychiatric disorder (TiC-P). *BMC health services research*. 2013 Jun;13:217.

Assessed for eligibility (n= 225)

Excluded (n= 131)

- ◆ Not meeting diagnostic criteria of BDD (n = 21)
- ◆ BDD not primary diagnosis (n = 18)
- ◆ Unstable medication (n = 5)
- ◆ Concurrent psychological treatment (n = 8)
- ◆ Bipolar disorder (n = 6)
- ◆ Declined to participate (n = 8)
- ◆ Unable to reach (n = 53)
- ◆ Other reason (n = 4)

Randomized (n= 94)

Allocated to BDD-NET (n= 47)

- ◆ Withdrew (n= 1)

Completed post-treatment interview (n= 47)

Completed post-treatment EQ-5D (n= 45)

Completed post-treatment TIC-P (n= 45)

Completed follow-up interview (n= 40)

Completed follow-up EQ-5D (n= 36)

Completed follow-up TIC-P (n= 36)

Intention to treat analysis (n= 47)

Allocated to supportive therapy (n= 47)

- ◆ Withdrew (n= 0)

Completed post-treatment interview (n= 47)

Completed post-treatment EQ-5D (n= 47)

Completed post-treatment TIC-P (n= 46)

Completed follow-up interview (n= 45)


Completed follow-up EQ-5D (n= 44)

Completed follow-up TIC-P (n= 43)

Intention to treat analysis (n= 47)


A

Remission status



B

QALY



C

ICER curves

